Zentraxa, Ltd.

Zentraxa, Ltd. specializes in precision engineering of bespoke biomaterials, offering innovative solutions to complex challenges in medical, industrial, and personal care industries. Founded in 2017 in Bristol, UK, Zentraxa, Ltd. operates as a spin-out from the University of Bristol.

The company focuses on the production of bespoke biomaterials and has successfully engaged in 4 deals. Recent funding activities include a Seed round on March 30, 2022, where it raised GBP 319 thousand from Bristol Private Equity Club, Future Planet Capital, and Science Angel Syndicate, bringing the total amount raised to GBP 319 thousand and resulting in a current company valuation of GBP 3. 575 mn. The firm was co-founded by Martin Challand, Mike Brownleader, Paul Race, and Steven Burston.

Zentraxa specializes in the precision engineering and production of bespoke biomaterials designed to address complex challenges across various industries, including medical, industrial, and personal care sectors. Their core product offerings include innovative peptide adhesives that enhance performance in advanced wound care, offering improved adhesion for wound dressings and ostomy bag seals in challenging conditions. Additionally, their adhesives are applicable in the security and optics fields, providing temporary adhesion for filters on optical sensors while maintaining optical clarity. The company targets a diverse client base, including healthcare providers, manufacturers in industrial sectors, and personal care brands, primarily serving markets in Europe, North America, and Asia-Pacific regions.

Zentraxa's revenue model primarily revolves around partnerships and direct sales to businesses in relevant industries. The company engages in B2B transactions, facilitating the integration of their performance-enhancing ingredients into clients' existing product lines and manufacturing processes. Clients may enter into agreements for bulk purchases of Zentraxa’s peptide adhesives or collaborate on joint development projects tailored to specific needs. The pricing structure is designed to reflect the customization and scalability of the solutions provided, with clients typically negotiating terms based on volume and integration requirements.

Notable product lines include their trademarked peptide adhesives, which are positioned as key solutions in advanced wound care and personal care applications, emphasizing the company's focus on delivering high-performance, bespoke biomaterials. In March 2022, Zentraxa, Ltd. raised GBP 319 thousand of Seed funding to expand the use of its platform technology and support product development. The company plans to leverage this funding to design new products tailored to meet the evolving needs of its clients and to explore expansion into new geographic markets, specifically targeting growth in North America and Asia-Pacific by 2023.

These initiatives aim to enhance their capabilities in delivering innovative biomaterials and to increase their market footprint.